A ‘Breakthrough’ Approach Redefining Critical Care for Sepsis in the ICU
Every year, sepsis claims 11 million lives. And survivors are often never the same.
It’s a $100B1 problem and there is currently no FDA-approved therapy that targets the cause. Through targeted innovation, Eliaz Therapeutics’ new investigational approach has been granted FDA Breakthrough Device Designation for the treatment of sepsis in the ICU. This is your opportunity to help reshape the future of critical care and join our community as an investor before the first-in-human trials are launched.2
Galectin-3: The Leading Culprit Behind ICU Deaths
Sepsis is driven by a dysregulated immune response in which Galectin-3 protein plays a central role. Galectin-3 acts as your body’s fire alarm stuck in the ON position. Galectin-3 tells the immune system to attack and keep attacking even after the threat is over. This is the body’s immune response turning against itself, leading to widespread inflammation and organ failure within hours. Despite its severity, treatment remains largely supportive, managing complications rather than directly addressing the underlying biology.
Our Approach Targets and Removes Galectin-3 from the Bloodstream
XGal-3 is designed to remove circulating Galectin-3 from the bloodstream, aiming to modulate the dysregulated immune response seen in sepsis. The process is similar to dialysis: blood flows through a single-use cartridge, where Galectin-3 is selectively captured, and filtered blood is returned to the patient without adding any drugs or other agents.
The device plugs into an existing hospital apheresis infrastructure, and utilizes a proprietary antibody-coated resin, which has demonstrated high Galectin-3 binding efficiency under controlled conditions.
Our device captures Galectin-3 to mitigate the inflammatory cascade leading to organ failure.
Uses antibody-coated resin to remove Galectin-3 directly from the blood.
Designed for early ICU intervention alongside standard critical care to prevent immune collapse.
Unlike broad filters, we selectively target the specific molecule driving the chaos.
Patient-safe. Single-use. Easy adoption.
Blood is "continiously" withdrawn from patient and directed into a specialized machine.
The machine separates the blood through centrifugation, and our device captures the Galectin-3.
The purified blood is then returned to the patient's body, relieving the effects of elevated Galectin-3 levels.
Published Proof, Breakthrough FDA Status, and 75+ Patents
Together, these elements support advancement toward first-in-human clinical trial and the ability to combine the XGal-3® with other treatments.
XGal-3® has received FDA Breakthrough Device Designation, a status granted to technologies that demonstrate the potential to address life-threatening conditions and unmet medical needs. This designation is reserved for devices that offer innovative solutions for life-threatening conditions like sepsis. It strengthens both the regulatory pathway and reimbursement/adoption pathway.
Our global intellectual property portfolio spans the antibody-based binding matrix, device architecture, and the therapeutic applications of Galectin-3 removal, supporting both current development and potential future indications.
Preclinical and translational findings have been published, including a large-animal study featured as a cover article in a high-tier peer-reviewed medical journal. In just 90 minutes, we saw key inflammatory and pathophysical markers shift in controlled sepsis models where selective Galectin-3 removal was associated with improved survival compared to controls.
Sepsis Patient Stories
Partnered with Terumo BCT For Global Collaboration & Distribution
Terumo BCT is a global leader in blood component and apheresis technologies, with a presence in nearly 200 countries. Since 2021, we have been partnered with Terumo BCT to support the development of XGal-3®. As part of this collaboration, Terumo BCT is supplying core apheresis platforms and disposables for our pre-clinical and clinical programs, enabling integration with established hospital infrastructure. This partnership provides a clear pathway to leverage existing global apheresis platforms and distribution capabilities as we advance toward commercialization.
A $100B+1 Market With No Current Approved Treatment2
Sepsis treatment is our FDA entry point, a $100B market on its own. But Galectin-3 also drives disease progression in fibrosis, oncology, chronic kidney disease, and heart failure. Once adopted for sepsis, this same device (XGAL-3®) treats adjacent conditions, with 75+ patents across 30+ countries protecting that expansion. If validated clinically, this approach could represent a broader platform for modulating systemic inflammatory and fibrotic processes. The full addressable market across the U.S. and EU exceeds $300B.3
Single-Use Design, Single Course of Care. Designed for the ICU.
Depending on the treatment protocol and patient condition, multiple columns may be used across consecutive ICU sessions, supporting repeat utilization within a single course of ICU stay.
The Path to FDA Approval
Q4 2025 – Q3 2026
Design freeze. Verification & validation testing.
Q1 2027
GLP safety studies.
Q2 – Q3 2027
First-in-human trials.
Q3 2027 – Q4 2028
Pivotal trials.
Q2 – Q3 2029
PMA submission.
Q1 2030
FDA approval.
Q2 2030
Commercial launch.
Groundbreaking Opportunity Is Priced Ahead Of Human Data
This round is intended to support GLP safety studies and first-in-human trials, with key milestones expected over the next 12–15 months.
Invest NowHow We’ll Use Your Investment
We're raising $3M to reach first-in-human trials and regulatory momentum.
What Investors Say
*The testimonials presented are the opinions of the individuals providing them. They may not represent the experience of all clients or investors and are not a guarantee of future performance or success.
Perks
30 Years of Galectin-3 Research
• Our founder, Dr. Isaac Eliaz, has spent over three decades researching Galectin-3 and its role in acute and chronic diseases. He founded EcoNugenics, a science-driven company focused on Galectin-3 biology, which produced an extensive body of published research and was acquired by Charlesbank, a leading private equity firm, in 2023.
• Dr. Eliaz has been researching therapeutic apheresis and offering apheresis treatments in his medical center since 2011.
• Dr. Eliaz is supported by a multidisciplinary team with experience across biomedical research, clinical development, engineering, and regulatory strategy, including experienced clinicians, scientists, and industry advisors, all contributing to the advancement of XGal-3® from concept toward clinical execution and commercialization.
MD, MS, LAc
Serial entrepreneur, clinical researcher, prior healthcare exit. Leading expertise in Gal-3 and apheresis.
MSC, MBA
Operations, Strategic partnerships, biotech commercialization
PHD
Biotech R&D leader across oncology, inflammation, and infectious disease therapeutics
MBA
Finance, Business modeling, and M&A
MBA
Background in MedTech and
HealthTech, partner to PE, VC & Founders
MD, PhD
Dr. Alpert brings decades of regulatory expertise, including 13 years at the FDA, where she served as Director of the Office of Device Evaluation (1993-1999). She will guide ETI through FDA pathways, optimizing submissions and securing key regulatory approvals for XGal-3®.
BA
Clinical operations background, support in business admin, marketing, and Investor Relations
Our World Class Scientific Advisory Board
%201.webp)
Professor of Medicine, Chief, Division of Nephrology at Stanford University School of Medicine
Nephrologist and Director of Hemodialysis at St.Michael's Hospital, and a Professor of Medicine at the University of Toronto
Mayo Clinic, Division of Transfusion Medicine, Professor of Laboratory Medicine & Pathology
Director of the Atherosclerosis & Lipid Apheresis Center, Associate Professor of Internal Medicine, University of Kansas Medical Center
Head of Genitourinary Oncology Unit at Tel AvivSourasky Medical Center
Frequently Asked Questions
Why invest in startups?
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
How much can I invest?
Accredited investors can invest as much as they want. The minimum investment is $1,000. If you are not an accredited investor, your investment limit depends on your annual income or net worth (whichever is greater): if that number is less than $124,000, you can invest up to 5% of it; if it’s $124,000 or more, you can invest up to 10%.
How do I calculate my net worth?
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Who can invest in a Regulation CF Offering?
Individuals over 18 years of age can invest.
What do I need to know about early-stage investing? Are these investments risky?
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
When will I get my investment back?
The Common Stock (the "Shares") of Eliaz Therapeutics (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Can I sell my shares?
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
Exceptions to limitations on selling shares during the one-year lockup period:
In the event of death, divorce, or similar circumstance, shares can be transferred to:
• The company that issued the securities;
• An accredited investor;
• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships).
What happens if a company does not reach their funding target?
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
How can I learn more about a company's offering?
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
What if I change my mind about investing?
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
How do I keep up with how the company is doing?
The company will file an annual report with the SEC and make it available on its website, together with the required financial statements. These reports are generally due within 120 days after the end of each fiscal year.
The company intends to provide periodic email communications and updates to investors regarding its progress and key developments. Under certain circumstances, including if the company becomes subject to other SEC reporting requirements or qualifies for an exemption from Regulation Crowdfunding reporting, the reporting described above may no longer be required. If that occurs, investors may not continue to receive the same information currently provided under Regulation Crowdfunding.
What relationship does the company have with DealMaker Securities?
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
What is Eliaz Therapeutics's pre-money implied valuation?
Eliaz Therapeutics’ pre-money implied valuation is $59,436,000. The terms of this Offering are based on a pre-money using the current issued and outstanding shares of the Company (and excluding shares to be issued upon conversion of convertible securities). The Securities are priced arbitrarily and the Company makes no representations as to the reasonableness of any specified valuation.